These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 20713045)

  • 1. Monitoring dyskinesia with Zif.
    Fisone G
    Exp Neurol; 2010 Nov; 226(1):11-4. PubMed ID: 20713045
    [No Abstract]   [Full Text] [Related]  

  • 2. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
    Carta AR; Frau L; Pinna A; Morelli M
    Exp Neurol; 2010 Aug; 224(2):395-402. PubMed ID: 20452347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of later phases of Parkinson disease].
    Tison F
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 8. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
    Brotchie JM
    Adv Neurol; 1999; 80():71-85. PubMed ID: 10410705
    [No Abstract]   [Full Text] [Related]  

  • 10. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 13. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic dopamine receptor interactions in the core and shell of nucleus accumbens differentially coordinate the expression of unconditioned motor behaviors.
    Canales JJ; Iversen SD
    Synapse; 2000 Jun; 36(4):297-306. PubMed ID: 10819907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopamine receptors and dyskinesias].
    Linazasoro G
    Neurologia; 1998 Apr; 13(4):206-7. PubMed ID: 9608763
    [No Abstract]   [Full Text] [Related]  

  • 16. [New perspectives in the treatment of the motor complications associated with chronic treatment of Parkinson disease].
    Linazasoro G
    Neurologia; 1999 Oct; 14(8):393-406. PubMed ID: 10609463
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors and L-dopa-induced dyskinesia.
    Berthet A; Bezard E
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S8-12. PubMed ID: 20123563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.